Results
1 -
10 of
11Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer, Targeted Oncology The Biology and Clinical Development of MEK Inhibitors for Cancer, Drugs Refametinib/sorafenib, Reactions Weekly Bayer mit gut gef??llter Onkologie-Pipeline, Im Focus Onkologie MEK and the inhibitors: from bench to bedside, Journal of Hematology & Oncology From basic research to clinical development of MEK1/2 inhibitors for cancer therapy, Journal of Hematology & Oncology Putting SMYD3 on the MAP, Science-Business eXchange Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts, BMC Cancer MAPping out aneurysm, Science-Business eXchange MAP kinase 3 (MAPK3; ERK-1); MAPK1 (ERK-2); MAP kinase kinase 1 (MAP2K1; MEK1); MAP2K2 (MEK2); c-jun N-terminal kinase 1 (JNK1; MAPK8), Science-Business eXchange